Jiri Suttnar

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9243191/publications.pdf

Version: 2024-02-01

62	767	14	25
papers	citations	h-index	g-index
62	62	62	1088
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Incorporation of Fibrin, Platelets, and Red Blood Cells into a Coronary Thrombus in Time and Space. Thrombosis and Haemostasis, 2022, 122, 434-444.	3.4	9
2	Long-Term Effects on the Lipidome of Acute Coronary Syndrome Patients. Metabolites, 2022, 12, 124.	2.9	3
3	Structural and Functional Characterization of Four Novel Fibrinogen Mutations in FGB Causing Congenital Fibrinogen Disorder. International Journal of Molecular Sciences, 2022, 23, 721.	4.1	3
4	Thrombosis-associated hypofibrinogenemia. Blood Coagulation and Fibrinolysis, 2022, Publish Ahead of Print, .	1.0	O
5	Extension of the Human Fibrinogen Database with Detailed Clinical Informationâ€"The αC-Connector Segment. International Journal of Molecular Sciences, 2022, 23, 132.	4.1	3
6	Low Plasma Citrate Levels and Specific Transcriptional Signatures Associated with Quiescence of CD34+ Progenitors Predict Azacitidine Therapy Failure in MDS/AML Patients. Cancers, 2021, 13, 2161.	3.7	2
7	Molecular Dynamic Simulations Suggest That Metabolite-Induced Post-Translational Modifications Alter the Behavior of the Fibrinogen Coiled-Coil Domain. Metabolites, 2021, 11, 307.	2.9	2
8	Lipidomic Analysis to Assess Oxidative Stress in Acute Coronary Syndrome and Acute Stroke Patients. Metabolites, 2021, 11, 412.	2.9	10
9	Fibrin Clot Formation under Oxidative Stress Conditions. Antioxidants, 2021, 10, 923.	5.1	5
10	The ω-3 Polyunsaturated Fatty Acids and Oxidative Stress in Long-Term Parenteral Nutrition Dependent Adult Patients: Functional Lipidomics Approach. Nutrients, 2020, 12, 2351.	4.1	9
11	Impact of posttranslational modifications on atomistic structure of fibrinogen. PLoS ONE, 2020, 15, e0227543.	2.5	16
12	Tryptophan Metabolism, Inflammation, and Oxidative Stress in Patients with Neurovascular Disease. Metabolites, 2020, 10, 208.	2.9	43
13	Hsp70 Trap Assay for Detection of Misfolded Subproteome Related to Myelodysplastic Syndromes. Analytical Chemistry, 2019, 91, 14226-14230.	6.5	1
14	A New Approach for the Diagnosis of Myelodysplastic Syndrome Subtypes Based on Protein Interaction Analysis. Scientific Reports, 2019, 9, 12647.	3.3	8
15	The effect of ω-3 polyunsaturated fatty acids on the liver lipidome, proteome and bile acid profile: parenteral versus enteral administration. Scientific Reports, 2019, 9, 19097.	3.3	11
16	Enhanced plasma protein carbonylation in patients with myelodysplastic syndromes. Free Radical Biology and Medicine, 2017, 108, 1-7.	2.9	12
17	Effect of Blood Component Coatings of Enosseal Implants on Proliferation and Synthetic Activity of Human Osteoblasts and Cytokine Production of Peripheral Blood Mononuclear Cells. Mediators of Inflammation, 2016, 2016, 1-15.	3.0	8
18	Protein Carbonylation in Patients with Myelodysplastic Syndromes. Blood, 2015, 126, 5232-5232.	1.4	1

#	Article	IF	Citations
19	Plasma Levels of Aminothiols, Nitrite, Nitrate, and Malondialdehyde in Myelodysplastic Syndromes in the Context of Clinical Outcomes and as a Consequence of Iron Overload. Oxidative Medicine and Cellular Longevity, 2014, 2014, 1-10.	4.0	21
20	A novel natural mutation A $\hat{l}\pm$ Phe98lle in the fibrinogen coiled-coil affects fibrinogen function. Thrombosis and Haemostasis, 2014, 111, 79-87.	3.4	7
21	Proteome Changes in the Plasma of Myelodysplastic Syndrome Patients with Refractory Anemia with Excess Blasts Subtype 2. Disease Markers, 2014, 2014, 1-8.	1.3	16
22	Abnormal Fibrinogen ZlÃn (γThr21lle) with Missense Mutation Causing Hypofibrinogenemia. Acta Haematologica, 2014, 132, 140-143.	1.4	2
23	No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia. Hematological Oncology, 2014, 32, 87-93.	1.7	5
24	Two novel mutations in the fibrinogen \hat{I}^3 nodule. Thrombosis Research, 2014, 134, 901-908.	1.7	6
25	Plasma proteome changes associated with refractory anemia and refractory anemia with ringed sideroblasts in patients with myelodysplastic syndrome. Proteome Science, 2013, 11, 14.	1.7	15
26	Staining of proteins for 2D SDSâ€PAGE using Coomassie Blueâ€"speed versus sensitivity?. Electrophoresis, 2013, 34, 1972-1975.	2.4	5
27	Enhanced levels of asymmetric dimethylarginine in a serum of middle age patients with myelodysplastic syndrome. Journal of Hematology and Oncology, 2013, 6, 58.	17.0	2
28	Novel homozygous fibrinogen \hat{Al}_{\pm} chain truncation causes severe afibrinogenemia with life threatening complications in a two-year-old boy. Thrombosis Research, 2013, 132, 490-492.	1.7	4
29	The Effect of Reagents Mimicking Oxidative Stress on Fibrinogen Function. Scientific World Journal, The, 2013, 2013, 1-8.	2.1	26
30	Proteomic analysis of plasma samples from acute coronary syndrome patients â€" The pilot study. International Journal of Cardiology, 2012, 157, 126-128.	1.7	2
31	Simplified platelet sample preparation for <scp>SDS</scp> â€ <scp>PAGE</scp> â€based proteomic studies. Proteomics - Clinical Applications, 2012, 6, 374-381.	1.6	5
32	Plasma protein alterations in the refractory anemia with excess blasts subtype 1 subgroup of myelodysplastic syndrome. Proteome Science, 2012, 10, 31.	1.7	12
33	Proteomic analysis of the plasma samples of patients with stable angina pectoris. Cor Et Vasa, 2012, 54, e22-e26.	0.1	1
34	Fibrinogen Åumperk II: Dysfibrinogenemia in an individual with two coding mutations. American Journal of Hematology, 2012, 87, 555-557.	4.1	10
35	Surface plasmon resonance biosensor for the detection of VEGFR-1â€"a protein marker of myelodysplastic syndromes. Analytical and Bioanalytical Chemistry, 2012, 402, 381-387.	3.7	53
36	Congenital dysfibrinogenemia Aα Gly13Glu associated with bleeding during pregnancy. Thrombosis Research, 2011, 127, 277-278.	1.7	11

#	Article	IF	Citations
37	Fibrinopeptides A and B release in the process of surface fibrin formation. Blood, 2011, 117, 1700-1706.	1.4	76
38	Plasma proteome changes associated with refractory cytopenia with multilineage dysplasia. Proteome Science, 2011, 9, 64.	1.7	18
39	Plasma proteome changes in cardiovascular disease patients: novel isoforms of apolipoprotein A1. Journal of Translational Medicine, 2011, 9, 84.	4.4	30
40	Two novel fibrinogen variants in the C-terminus of the $\mathrm{B}\hat{\mathrm{I}}^2$ -chain: fibrinogen Rokycany and fibrinogen Znojmo. Journal of Thrombosis and Thrombolysis, 2010, 30, 311-318.	2.1	15
41	Dysfibrinogenemia in childhood: two cases of congenital dysfibrinogens. Blood Coagulation and Fibrinolysis, 2010, 21, 640-648.	1.0	7
42	Proteome changes in platelets activated by arachidonic acid, collagen, and thrombin. Proteome Science, 2010, 8, 56.	1.7	44
43	Two cases of congenital dysfibrinogenemia associated with thrombosis – Fibrinogen Praha III and Fibrinogen PlzeÅ^. Thrombosis and Haemostasis, 2009, 102, 479-486.	3.4	22
44	Antioxidants change platelet responses to various stimulating events. Free Radical Biology and Medicine, 2009, 47, 1707-1714.	2.9	33
45	A novel fibrinogen variant $\hat{a}\in$ Liberec: dysfibrinogenaemia associated with \hat{l}^3 Tyr262Cys substitution. European Journal of Haematology, 2008, 81, 123-129.	2.2	11
46	Acquired Dysfibrinogenemia Secondary to Multiple Myeloma. Acta Haematologica, 2008, 120, 75-81.	1.4	34
47	Three cases of abnormal fibrinogens: Åumperk (Bβ His67Leu), Uniãov (Bβ Gly414Ser), and Brno (γArg275His). Thrombosis and Haemostasis, 2008, 100, 1199-1200.	3.4	4
48	Three cases of abnormal fibrinogens: sumperk (Bbeta His67Leu), Unicov (Bbeta Gly414Ser), and Brno (gammaArg275His). Thrombosis and Haemostasis, 2008, 100, 1199-200.	3.4	1
49	Fibrinogen Nový JiÄÃn and Praha II: Cases of hereditary Aα 16 Argâ†'Cys and Aα 16 Argâ†'His dysfibrinogenemi Thrombosis Research, 2007, 121, 75-84.	ia 1.7	20
50	A novel fibrinogen variant? Praha I: hypofibrinogenemia associated with? Gly351Ser substitution. European Journal of Haematology, 2007, 78, 410-416.	2.2	12
51	The adhesion of blood platelets on fibrinogen surface: Comparison of two biochemical microplate assays. Platelets, 2006, 17, 470-476.	2.3	32
52	Determination of the Putative Binding Sites for Thrombin Receptor Activating Peptide through a Hydropathic Complementary Approach. Thrombosis and Haemostasis, 2000, 83, 165-170.	3.4	1
53	Surface plasmon resonance analysis of immobilized fibrinogen and fibrin and their interaction with thrombin and fibrinogen., 1999, 3570, 176.		O
54	Platelet Adhesion to Fibrinogen, Fibrin Monomer, and Fibrin Protofibrils in Flowing Blood - The Effect of Fibrinogen Immobilization and Fibrin Formation. Thrombosis and Haemostasis, 1997, 78, 1125-1131.	3.4	26

#	Article	IF	CITATIONS
55	Characterization of Platelet Antigen for CD45RA Monoclonal Antibodies. Immunobiology, 1995, 192, 272-277.	1.9	2
56	EDMA 2000 as a matrix for high-performance liquid chromatography of human haemoglobin chains. Biomedical Applications, 1994, 656, 119-122.	1.7	1
57	Production and simple purification of a protein encoded by part of the gag gene of HIV-1 in the Escherichia coli HB101F+ expression system inducible by lactose and isopropyl-β-d-thiogalactopyranoside. Biomedical Applications, 1994, 656, 127-133.	1.7	3
58	Comparison of rat and human major platelet glycoproteins. Comparative Biochemistry and Physiology Part B: Comparative Biochemistry, 1991, 99, 399-403.	0.2	4
59	The action of a fibrin-promoting enzyme from the venom of Agkistrodon contortrix contortrix on rat fibrinogen and plasma. Toxicon, 1990, 28, 1364-1367.	1.6	2
60	Distortion of the electrophoretic titration curves of some proteins. Electrophoresis, 1989, 10, 704-708.	2.4	3
61	Fibrinopeptide-releasing enzymes in the venom from the southern copperhead snake (Agkistrodon) Tj ETQq1 1 C).784314 1.6	rgBT/Overloc 12
62	On the molecular conformation of human haemopexin. Biochimica Et Biophysica Acta (BBA) - Protein Structure, 1977, 495, 260-267.	1.7	5